[go: up one dir, main page]

CL2016002772A1 - Composiciones de insulina de rápida acción - Google Patents

Composiciones de insulina de rápida acción

Info

Publication number
CL2016002772A1
CL2016002772A1 CL2016002772A CL2016002772A CL2016002772A1 CL 2016002772 A1 CL2016002772 A1 CL 2016002772A1 CL 2016002772 A CL2016002772 A CL 2016002772A CL 2016002772 A CL2016002772 A CL 2016002772A CL 2016002772 A1 CL2016002772 A1 CL 2016002772A1
Authority
CL
Chile
Prior art keywords
fast
acting insulin
insulin compositions
compositions
acting
Prior art date
Application number
CL2016002772A
Other languages
English (en)
Inventor
Michael Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2016002772A1 publication Critical patent/CL2016002772A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>COMPOSICION FARMACÉUTICA QUE COMPRENDE INSULINA Y TREPROSTINIL.</p>
CL2016002772A 2014-05-08 2016-11-02 Composiciones de insulina de rápida acción CL2016002772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08

Publications (1)

Publication Number Publication Date
CL2016002772A1 true CL2016002772A1 (es) 2017-06-09

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002772A CL2016002772A1 (es) 2014-05-08 2016-11-02 Composiciones de insulina de rápida acción

Country Status (36)

Country Link
US (2) US9439952B2 (es)
EP (3) EP3536380B8 (es)
JP (1) JP6050902B2 (es)
KR (1) KR101858890B1 (es)
CN (1) CN106456717B (es)
AP (1) AP2016009525A0 (es)
AR (1) AR100155A1 (es)
AU (1) AU2015256355B2 (es)
BR (1) BR112016024357B1 (es)
CA (1) CA2945188C (es)
CL (1) CL2016002772A1 (es)
CY (2) CY1121669T1 (es)
DK (2) DK3536380T3 (es)
EA (1) EA031134B1 (es)
ES (2) ES2733639T3 (es)
HR (2) HRP20190777T1 (es)
HU (2) HUE055742T2 (es)
IL (1) IL248350B (es)
JO (1) JO3624B1 (es)
LT (2) LT3536380T (es)
MA (1) MA39441A1 (es)
ME (1) ME03384B (es)
MX (1) MX367521B (es)
NZ (1) NZ724919A (es)
PE (1) PE20161408A1 (es)
PH (1) PH12016502195B1 (es)
PL (2) PL3536380T3 (es)
PT (2) PT3140008T (es)
RS (2) RS62291B1 (es)
SG (1) SG11201608424WA (es)
SI (2) SI3536380T1 (es)
TN (1) TN2016000443A1 (es)
TR (1) TR201906843T4 (es)
TW (1) TWI685348B (es)
UA (1) UA124919C2 (es)
WO (1) WO2015171484A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
DK2919804T3 (en) 2012-11-13 2018-05-14 Adocia Rapidly acting insulin formulation comprising a substituted anionic compound
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
US20180221385A1 (en) * 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN108778249B (zh) * 2016-01-29 2022-05-27 曼金德公司 干粉吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
JP7145849B2 (ja) 2016-09-29 2022-10-03 アレコル リミテッド 新規の製剤
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
MA50496A (fr) * 2017-06-01 2020-09-09 Lilly Co Eli Compositions d'insuline à action rapide
IL277731B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
CN112040928A (zh) 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) * 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CA3149358A1 (en) 2019-08-23 2021-03-04 United Therapeutics Corporation Treprostinil prodrugs
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
EP4135707A1 (en) 2020-04-17 2023-02-22 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
WO2021252446A1 (en) 2020-06-09 2021-12-16 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
WO2022002008A1 (zh) * 2020-06-30 2022-01-06 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途
AU2021401921A1 (en) 2020-12-14 2023-07-06 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
US20250288597A1 (en) * 2022-04-29 2025-09-18 Zhaoke Pharmaceutical (Guangzhou) Co., Ltd Treprostinil soft mist inhalant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
MXPA04001560A (es) * 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
EP1506230B1 (en) * 2002-05-07 2011-01-19 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
ES2340939T3 (es) * 2004-04-12 2010-06-11 United Therapeutics Corporation Utilizacioin del treprostinil para tratar las ulceras de pie diabeticas neuropaticas.
EP2190433A2 (en) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (en) * 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
PL2612677T3 (pl) * 2009-06-26 2015-10-30 Novo Nordisk As Preparat zawierający insulinę, nikotynamid i argininę
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
EP2651446A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
MX349950B (es) * 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2015031709A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
EP3536380B1 (en) 2021-07-07
HUE044370T2 (hu) 2019-10-28
EP3536380B8 (en) 2021-09-22
AU2015256355A1 (en) 2016-10-27
LT3140008T (lt) 2019-05-27
TN2016000443A1 (en) 2018-04-04
ES2733639T3 (es) 2019-12-02
MX367521B (es) 2019-08-26
EP3140008B1 (en) 2019-04-17
CN106456717A (zh) 2017-02-22
CY1124454T1 (el) 2022-07-22
PT3140008T (pt) 2019-06-25
HUE055742T2 (hu) 2021-12-28
AU2015256355B2 (en) 2017-09-14
EA201691911A1 (ru) 2017-02-28
ME03384B (me) 2020-01-20
JP6050902B2 (ja) 2016-12-21
LT3536380T (lt) 2021-08-10
DK3140008T3 (da) 2019-06-24
AR100155A1 (es) 2016-09-14
SI3536380T1 (sl) 2021-09-30
IL248350A0 (en) 2016-11-30
BR112016024357B1 (pt) 2022-08-23
CN106456717B (zh) 2020-01-17
SI3140008T1 (sl) 2019-06-28
KR20160133567A (ko) 2016-11-22
TWI685348B (zh) 2020-02-21
SG11201608424WA (en) 2016-11-29
MX2016014643A (es) 2017-03-06
US10172922B2 (en) 2019-01-08
PL3140008T3 (pl) 2019-09-30
JP2016523807A (ja) 2016-08-12
EP3536380A1 (en) 2019-09-11
PT3536380T (pt) 2021-09-02
RS62291B1 (sr) 2021-09-30
EP3140008A1 (en) 2017-03-15
DK3536380T3 (da) 2021-08-02
EA031134B1 (ru) 2018-11-30
US20160367640A1 (en) 2016-12-22
WO2015171484A1 (en) 2015-11-12
US9439952B2 (en) 2016-09-13
JO3624B1 (ar) 2020-08-27
AP2016009525A0 (en) 2016-10-31
TR201906843T4 (tr) 2019-05-21
IL248350B (en) 2020-03-31
HRP20211415T1 (hr) 2021-12-10
BR112016024357A2 (pt) 2017-10-10
KR101858890B1 (ko) 2018-05-16
ES2891983T3 (es) 2022-02-01
EP3943155A1 (en) 2022-01-26
CY1121669T1 (el) 2020-07-31
CA2945188C (en) 2018-12-11
MA39441A1 (fr) 2017-06-30
PH12016502195A1 (en) 2017-02-06
PL3536380T3 (pl) 2021-12-27
CA2945188A1 (en) 2015-11-12
US20160129087A1 (en) 2016-05-12
PH12016502195B1 (en) 2017-02-06
TW201625291A (zh) 2016-07-16
HRP20190777T1 (hr) 2019-08-23
UA124919C2 (uk) 2021-12-15
RS58726B1 (sr) 2019-06-28
PE20161408A1 (es) 2016-12-28
NZ724919A (en) 2018-01-26

Similar Documents

Publication Publication Date Title
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2017000649A1 (es) Composiciones que contengan células de bacilo recombinantes y un insecticida
GEP20217239B (en) Pharmaceutical composition
BR112017000039A2 (pt) composições agrícolas e aplicações que utilizam óleos essenciais
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
DK3233108T3 (da) Hurtigtvirkende insulinsammensætninger
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
BR112016023628A2 (pt) composições farmacêuticas.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
PT3340966T (pt) Composições de insulina de ação rápida
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
PL3293188T3 (pl) Silany i utwardzalne kompozycje obejmujące wskazane silany
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
GEP20217240B (en) Pharmaceutical composition
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX2015008588A (es) Composiciones y metodos para la transfeccion de polinucleótidos.
SI3220893T1 (sl) Sestavek na osnovi COQ10
AR104591A1 (es) Piroglutamato de vortioxetina
MX379126B (es) Formulación de factor viii.
DK3331498T3 (da) Nasalsammensætning
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
EP3153492A4 (en) Novel compound and fragrance composition containing same
PH12015502061A1 (en) Racecadotril liquid compositions
ES1216222Y (es) Composicion que comprende cenizas de cremacion